Evidence map›Paper›PMID 38157402›Full record

Trial reportThe Journal of infectious diseases2024

A Multiseason Randomized Controlled Trial of Advax-Adjuvanted Seasonal Influenza Vaccine in Participants With Chronic Disease or Older Age.

Dimitar Sajkov, Richard Woodman, Yoshikazu Honda-Okubo, Jeffrey Barbara, Derek Chew, Barbara Toson, Nikolai Petrovsky

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Polysaccharide Extracted from Longan (International journal of molecular sciences · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Dimitar SajkovAustralian Respiratory and Sleep Medicine Institute Ltd, Clovelly Park, South Australia, Australia.
Richard WoodmanEpidemiology and Biostatistics, Flinders University, Bedford Park, South Australia, Australia.
Yoshikazu Honda-OkuboVaxine Pty Ltd, Warradale, South Australia, Australia.
Jeffrey BarbaraRenal Department, Flinders University, Bedford Park, South Australia, Australia.
Derek ChewCardiology Department, Flinders University, Bedford Park, South Australia, Australia.
Barbara TosonCollege of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia.
Nikolai PetrovskyAustralian Respiratory and Sleep Medicine Institute Ltd, Clovelly Park, South Australia, Australia.ORCID 0000-0002-1580-5245
Flinders University · AUVaxine (Australia) · AU

Funding

Novel vaccine adjuvants to counter bioterrorist threatsU01AI061142 · NIAID · FLINDERS UNIVERSITY OF SOUTH AUSTRALIA · PI PETROVSKY, NIKOLAI · 2005 to 2009
$3.5M
Flinders Medical CentreNational Institute of Allergy and Infectious DiseasesNIAID NIH HHS HHSN272200800039CNIAID NIH HHS U01 AI061142NIH HHS U01-AI061142Vaxine
6 · The paper itself

Abstract

backgroundThe aim of the current study was to determine the safety and immunogenicity of trivalent inactivated influenza vaccine (TIV) alone or formulated with Advax delta inulin adjuvant in those who were older (aged >60 years) or had chronic disease.

methodsOver 4 consecutive years from 2008 through 2011, adult participants with chronic disease or >60 years of age were recruited into a randomized controlled study to assess the safety, tolerability and immunogenicity of Advax-adjuvanted TIV (TIV + Adj) versus standard TIV. The per-protocol population with ≥1 postbaseline measurement of influenza antibodies comprised 1297 participants, 447 in the TIV and 850 in the TIV + Adj) group.

resultsNo safety issues were identified. Variables negatively affecting vaccine responses included obesity and diabetes mellitus. Advax adjuvant had a positive impact on anti-influenza immunoglobulin M responses and on H3N2 and B strain seropositivity as assessed by hemagglutination inhibition.

conclusionsTIV + Adj was safe and well tolerated in individuals with chronic disease. There is an ongoing need for research into improved influenza vaccines for high-risk populations. CLINICAL TRIALS REGISTRATION: Australia New Zealand Clinical Trial Registry: ACTRN 12608000364370.

Indexed as

Antibodies, ViralInfluenza, HumanInfluenza VaccinesAdjuvants, VaccineAdultAgedAged, 80 and overChronic DiseaseFemaleHemagglutination Inhibition TestsHumansImmunogenicity, VaccineInfluenza A Virus, H3N2 SubtypeInfluenza B virusMaleMiddle AgedAdjuvants, VaccineAntibodies, ViralInfluenza VaccinesVaccines, InactivatedadjuvantAdvaxchronic diseaseinfluenzavaccine

Identifiers

PMID38157402
PMCPMC11326838
OpenAlexW4390393600

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.